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ABSTRACT The cytoplasmic form of protein kinase C (PKC) is inactive, probably because the pseudosubstrate region in its
regulatory domain blocks the substrate-binding site in its kinase domain. Calcium ions cause a translocation to the membrane:
maximum activation requires a negative lipid such as phosphatidylserine (PS) and the neutral lipid diacylglycerol (DAG) but the
mechanism by which PS and DAG activate PKC is unknown. Pseudosubstrate region 19-36 of PKC-3 has six basic and one acidic
amino acids and region 19-29 has five basic and no acidic amino acids. Since any binding of basic residues in the
pseudosubstrate region to acidic lipids in the membrane should stabilize the active form of PKC, we studied how peptides with
amino acids equivalent to residues 19-36 and 19-29 of PKC-3 bound to phospholipid vesicles. We made equilibrium dialysis,
filtration, and electrophoretic mobility measurements. The fraction of bound peptide is a steep sigmoidal function of the mol fraction
of negative lipid in the membrane, as predicted from a simple theoretical model that assumes the basic residues provide identical
independent binding sites. The proportionality constant between the number of bound peptides/area and the concentration of
peptide in the bulk aqueous phase is 1 ,um for a membrane with 25% negative lipid formed in 0.1 M KCI. Equivalently, the
association constant of the peptide with the membrane is 104 M-1, or the net binding energy is 6 kcal/mol. Thus the interaction of
basic residues in the pseudosubstrate region with acidic lipids in the membrane could provide 6 kcal/mol free energy towards
stabilizing the active form of PKC.
INTRODUCTION
Protein kinase C (PKC), an enzyme that phosphorylates
serine and threonine residues (1, 33, 37, 54-56, 58), is
an important component of the calcium/phospholipid
second messenger system (7-9). The binding of a variety
of hormones, neurotransmitters, or growth factors to
receptors activates a phospholipase C that catalyzes the
hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) into the two second messengers inositol 1,4,5-
trisphosphate (1P3) and diacylglycerol (DAG). DAG is
also formed by the breakdown of phosphatidylcholine
(24). 1P3 diffuses through the cytoplasm and releases
calcium ions from vesicular organelles. When the cell is
quiescent (concentration of free calcium < 10-7 M), a
significant fraction of PKC molecules reside in the
cytoplasm and are inactive. When the intracellular
concentration of free calcium rises, PKC "translocates"
to or binds to the plasma membrane and actively
phosphorylates its substrates (54, 65, 68). In cell-free
systems, the neutral lipid DAG and the negatively
charged phospholipid phosphatidylserine (PS) are re-
quired in the membrane for maximal activation
(27, 28, 56, 58).
House and Kemp (30) hypothesized that the regula-
tory domain of PKC contains a pseudosubstrate region
that interacts with a substrate binding site in the kinase
domain, rendering it inactive. They noted that the amino
acid sequence between residues 19 and 36 of PKC
resembled a phosphorylation site, then showed that the
corresponding synthetic peptide antagonizes substrate
phosphorylation by PKC. Makowske and Rosen (44)
provided strong support for the hypothesis by showing
that antiserum raised against this peptide activates PKC
in the absence of calcium and lipids. Hannun and Bell
(27) also concluded that their kinetic data support this
model.
The most highly developed model for PKC activation
is based on studies with mixed micelles (27). In this
model: "The enzyme first associates with the surface of
mixed micelles in the presence of PS and Ca2" but
remains inactive. In the second step, the enzyme be-
comes activated upon DAG or phorbol ester binding."
However, it is not clear how PKC binds to the membrane
(5, 43), why binding is usually a prerequisite for activa-
tion, and whether negatively charged lipids such as PS
are required in the membrane for both binding and
activation. We hypothesize that basic residues located in
the pseudosubstrate region of PKC bind to acidic lipids
located on the cytoplasmic surface of the plasma mem-
brane, and that this interaction stabilizes the active form
of the enzyme.
To investigate this hypothesis, we measured how
strongly peptides identical to regions 19-29 and 19-36 of
the PKC-P isotype bind to membranes containing nega-
tive lipids. These peptides have five and six basic
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residues, respectively, and both have a net charge of +5.
The first dozen residues of the pseudosubstrate region in
the other five well-characterized isotypes also have four
to six basic residues (58). Another objective was to test
how well the binding of these peptides to membranes
could be described by a simple theoretical expression.
Our theoretical model predicts that the binding of these
peptides to membranes should depend sigmoidally (i.e.,
with a high Hill coefficient, or high apparent cooperativ-
ity) on the mol fraction of negative lipid in the mem-
brane, as does the activity of PKC (12, 27, 28, 52).
Finally, we wanted to compare the binding observed
with these peptides to the binding observed with a
shorter, simpler peptide that has five basic residues,
pentalysine (38).
THEORY
we discuss the evidence that only four basic residues
combine with acidic lipids), that all binding sites are
identical and independent, that each site binds to a
negatively charged lipid with an identical net free energy
or intrinsic, microscopic' association constant, k, and
that zwitterionic lipids do not bind to the peptides. We
describe the binding with mass action equations. We
follow Guggenheim and assume the interactions occur
in a surface phase of thickness d - 1 nm, which we
regard as an ideal solution. If we follow Gibbs and
assume the reactions occur on a two-dimensional sur-
face that lacks finite thickness, we obtain mathematically
identical expressions.
We define the effective binding constant of a peptide
to the membrane, K, as the proportionality constant that
relates the concentration of peptide in the bulk aqueous
phase, [P], to the number of peptide molecules bound to
a unit area of surface, {P}:
We use the simplest theoretical model capable of
describing the binding of charged peptides to mem-
branes (16, 38). In brief, charged lipids such as PS or PG
produce an electrostatic potential at the surface of a
membrane, 4(0), which we describe by the Gouy-
Chapman-Stem theory of the aqueous diffuse double
layer (46). This negative potential increases the concen-
tration of the positvely charged peptides in the aqueous
phase immediately adjacent to the membrane. We
assume the peptide is a point charge and describe the
accumulation by the Boltzmann relation. Of course the
peptide is not a point charge; it is larger than the
thickness of the diffuse double layer, the Debye length,
which is 1 nm in a 0.1 M salt solution. Thus not all the
charges on the peptide will experience the full value of
the surface potential. For this and other reasons, we use
an effective valence, Zeff, that is less than the real valence
in the Boltzmann relation.' To calculate the net charge/
area on the membrane, we assume each adsorbed
peptide has its real valence, z = 5.
We assume that the two peptides we studied both
have four binding sites for acidic lipids (in the Appendix
{P} = K[P]. (1)
K has the units of length. We determine K experimen-
tally with either equilibrium dialysis or filtration experi-
ments. In terms of our theoretical model,K is given by
K = (exp (-zeffeeiJ(O)IkT))(4k{L )(1 + (312)(kld){L}
+ (kld)2{L}2 + (1I4)(kId)3(L}3). (2)
{L) is the number of negatively charged lipids per unit
area of membrane and IL )/d is the concentration of the
lipid in the surface phase of thickness d. The term in the
first pair of large parentheses describes the Boltzmann
accumulation of the peptide in the aqueous phase
adjacent to the membrane. The term in the second pair
of large parentheses describes the binding of a lipid to
one of the four identical sites on the peptide. The term
in the third pair of large parentheses describes the
binding of lipids to the three remaining binding sites on
the peptide. The numerical factors in the second and
third terms arise because of statistical effects (see
reference 14).
'There are at least four reasons why the effective valence, Zeff, in the
Boltzmann term of Eq. 2 is less than the real valence of the peptide.
First, the finite size of the peptide limits the distance of closest
approach. Thus the charges on the peptide do not experience the full
surface potential but the potential at some distance from the mem-
brane. Second, the finite size of the peptide affects its distribution in
the diffuse double layer (15). Third, discreteness-of-charge effects may
be important for these multivalent ions (41; Stankowski, S., personal
communication). Fourth, anions such as chloride may bind to the
peptide. In the Appendix we consider the experimental evidence that
the formal value of the effective valence in Eq. 2 is about half the true
valence of the three pentavalent peptides pentalysine, PKC(19-29) and
PKC(19-36).
MATERIALS AND METHODS
We obtained similar results with egg and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (PC), with bovine brain and 1-palmitoyl-2-
2The adjectives microscopic and macroscopic refer to association
constants defined with respect to individual sites on the peptide or to
the entire peptide (14, see pages 850-852 and 862; 38). The adjective
intrinsic refers to the assumption that all electrostatic effects are
accounted for by the mean field Gouy-Chapman theory and Boltz-
mann relation, the term in the first set of large parentheses in Eq. 2.
The net free energy change calculated from RT In (k) is the sum of all
the free energy terms involved in the binding-including the terms that
must describe the loss of entropy that occurs (10, 19, 35).
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oleoyl-sn-glycero-3-phosphoserine (PS), and with egg and 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphoglycerol (PG). The lipids were obtained
from Avanti Polar Lipids (Birmingham, AL).
The peptides PKC(19-29) and PKC(19-36) were obtained from
Multiple Peptide Systems (San Diego, CA). The peptide PKC (19-36)
has the sequence acetyl-Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-
Lys-Asn-Val-His-Glu-Val-Lys-Asn-amide. Purity of the peptides was
checked by amino acid analysis as well as by analytical HPLC using
both reverse phase and ion exchange chromatography with detection
at A.. The purity of PKC(19-36) was > 98%. PKC(19-29) required
additional purification using reverse phase HPLC to increase purity to
95%.
4-Morpholinepropanesulfonic acid (MOPS) was purchased from
Pharmacia Fine Chemicals (Piscataway, NJ). Aqueous solutions were
prepared with 18 Mfl water (Super-Q, Millipore Corp., Bedford, MA)
that was subsequently bidistilled in an all-quartz still. They were
buffered to pH 7.0 with 0.1-1 mM MOPS.
Multilamellar vesicles were used for the microelectrophoresis mea-
surements (3). We measured the mobilities of these vesicles in a Rank
Brothers Mark I instrument (Bottisham, Cambridge, UK) as described
previously (13, 47). Equilibrium dialysis and ultrafiltration experi-
ments were performed as described previously (38). The results
obtained with PKC(19-36) were corrected for the 11% free peptide
that appeared to bind to the ultrafiltration membrane.
RESULTS
We first consider a peptide identical to residues 19-36 of
PKC-,, i.e., the pseudosubstrate region (30, 36, 44, 58).
This peptide, PKC(19-36), has the sequence acetyl-Arg-
Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val-
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FIGURE 1 Binding of a peptide identical to residues 19-36 of PKC-p
to large unilamellar vesicles (LUVs) formed from mixtures of the
zwitterionic lipid PC and the negatively charged lipid PG. The aqueous
solutions contained 0.1 M KCI (open circles) or 0.01 M KCI (filled
circles) buffered to pH 7.0 with 1 mM MOPS, T = 25°C. They also
contained 10 mM lipid (PG plus PC) and 30 ,uM PKC(19-36) peptide.
The solid curve illustrates the prediction of Eq. 2, which ascribes the
sigmoidal nature of the binding to a combination of electrostatics and
reduction of dimensionality. The dashed curve illustrates the predic-
tions of a Hill equation with a Hill coefficient of 5, which provides a
satisfactory fit but a physically incorrect interpretation of the data.3
His-Glu-Val-Lys-Asn-amide. It has three arginine, three
lysine, and one glutamic acid residues and should thus
have a charge of +5 in a pH 7 solution. The open
circles in Fig. 1 illustrate how the binding of this peptide
to large unilamellar vesicles (LUVs) formed in 0.1 M
KCl depends on the mol % negative lipid in the
membrane. (The results in Fig. 1 were obtained from
filtration measurements; identical results were obtained
from control equilibrium dialysis measurements on 2:1
PC/PG vesicles.) There is no significant binding to
membranes formed with either 0 or 10% negative lipid.
The binding increases steeply with the PG content of the
membrane: >95% of the peptide is bound to vesicles
formed with 50% negatively charged lipid.
The sigmoidal3 binding curve arises for two reasons.
First, the negatively charged lipids produce an electro-
static potential in the aqueous phase immediately adja-
cent to the membrane. This potential accumulates
postively charged peptides in the aqueous diffuse double
layer, which increases the fraction of bound peptide.
Second, an increase in the mol fraction of negative lipid
increases the binding of the peptide to the membrane
because of mass action; the peptide does not bind to the
zwitterionic lipid PC but can bind more than one
negatively charged lipid, such as PG.
The solid curve in Fig. 1 illustrates the prediction of
Eq. 2. The curve is drawn with the value of k, the
intrinsic- microscopic2 association constant of a basic
residue on the peptide with an acidic lipid in the
membrane equal to 3.5 M-l, a value that gave a better
least square (and visual) fit to the data than either 3.0 or
4.0. Thus the net free energy2 of interaction of a basic
3The sigmoidal dependence of the percent bound peptide on the
concentration of negative lipid in the membrane (Fig. 1) resembles the
sigmoidal dependence of the binding of oxygen to hemoglobin. When
cooperative reactions occur in three dimensions they can be described
by a Hill equation; the Hill coefficient is a measure of the steepness of
the sigmoidal relation and reflects the degree of cooperativity of the
reaction. A Hill coefficient > 1 for a reaction in three dimensions
implies the binding of the first ligand produces an allosteric change
that increases significantly the association constant of the second
ligand. The data in Fig. 1 can also be described by an expression that is
formally identical to the Hill equation. We assume an infinitely
cooperative reaction occurs in the bulk aqueous phase between n
soluble acidic lipids, L, and a peptide, P. It follows that the fraction of
bound peptide is equal to (K*[L])nl/(1 + (K*[L])n), where K* is a
constant. This equation, with a Hill coefficient of n = 5 (dashed line in
Fig. 1) can describe the binding data obtained with PKC(19-36), as
well as the essentially identical data obtained with pentalysine (51).
However, this is not the correct interpretation of our measurements. It
is highly unlikely that the binding of an acidic lipid to one basic residue
on these simple peptides increases the association constants of the
other residues for acidic lipids by orders of magnitude. Furthermore,
our model predicts the marked increase in binding observed when the
salt concentration decreases (Fig. 1).
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residue and an acidic lipid is weak, RTln(k) - 1
kcal/mol. (As discussed in the Appendix, the effective
valence of the peptide that appears in Eq. 2 was assumed
to be Zeff = 2.5, half the actual valence of the peptide.)
Our interpretation of Eq. 2 and the data in Fig. 1
follows Guggenheim and considers the polar head group
region to be a surface phase of thickness d, where d is of
order 1 nm. Recall that {L} = number of acidic lipids/
area. When the product of the binding constant, k, and
the concentration of acidic lipid in the surface phase,
{L )Id, is < 1, the collection of terms in the third set of
large parentheses in Eq. 2 is of order unity. For k =
4 M-l, this occurs for {L }/d < 0.25 M (equivalent to 10
mol % acidic lipid or {L} = 1 lipid/7nm2). Thus, for a
membrane with < 10% PG, the peptide combines mainly
with one negative lipid, as described by the term in the
second set of large parentheses in Eq. 2, and the binding
is very weak, as is observed experimentally in Fig. 1.
Conversely, when k{L )Id > 1, the last term in the third
set of large parentheses in Eq. 2 dominates the other
terms. Thus for membranes with > 10% PG, the effec-
tive binding constant depends on a high power of the
percent PG in the membrane because the peptide
combines with more than one negative lipid. This
contributes to the steep sigmoidal nature of the binding
illustrated in Fig. 1.
In terms of the Guggenheim model of a surface phase
of finite thickness, the binding of acidic lipids appears to
be a cooperative process because the binding of the first
acidic lipid to a basic residue on the peptide places the
other residues in a phase where the concentration ofPG
is sufficiently high (for membranes with > 10% PG) that
most of the remaining binding sites combine with PG. In
the mathematically equivalent Gibbs model of a surface,
the interface is an infinitely thin dividing plane and
acidic lipid concentrations are expressed in terms of
number per unit area (e.g., IL }) rather than volume (e.g.,{L)Id). In terms of this model, the binding of one residue
reduces the dimensionality of the further reactions and
allows other binding sites to interact with acidic lipids.
We discuss this apparent cooperativity3 in the binding of
acidic lipids to peptides in more detail elsewhere (38, 51).
Although the sigmoidal nature of the solid curve in
Fig. 1 arises from both electrostatics and a transfer to a
separate phase that contains a high concentration of
ligand (or, equivalently, reduction of dimensionality), it
is easy to demonstrate that electrostatics alone strongly
affects the binding of this pentavalent peptide. The filled
circles illustrate binding measurements made in 0.01
rather than 0.1 M KCl: decreasing [KCl] dramatically
increases the binding of the peptide. For a vesicle
containing 10% PG, the percent bound peptide in-
creases from 0 to 90%. For a vesicle containing 17%
PG the percent bound peptide increases from 20 to
99%. This dramatic increase in binding occurs because
decreasing the salt concentration increases the magni-
tude of the negative electrostatic potential at the surface
of the membrane (j(0) in Eq. 2). The results illustrated
in Fig. 1 for the PKC(19-36) peptide in both 0.1 and
0.01 M KCl are essentially identical to those obtained
with the shorter, simpler pentavalent peptide Lys, (Mo-
sior, M., and S. McLaughlin, unpublished data).
To illustrate that the binding of the peptide to the
membrane depends on the mol fraction of negatively
charged lipid even when the surface potential is main-
tained at a constant value, we consider the effect of the
peptide on the zeta potential. Fig. 2 illustrates the effect
of PKC(19-36) on the zeta potential of phospholipid
vesicles. The zeta potential is the electrostatic potential
0.2 nm from the surface of the membrane (2, 20, 23, 60)
and is approximately the surface potential, f(0) in Eq. 2.
This potential is (approximately) proportional to the net
charge density at the surface of the membrane, and is
thus linearly related to the number of peptides bound to
a unit area of membrane. PKC(19-36) does not bind
significantly to PC vesicles: 100 p,M peptide does not
change the zeta potential of a PC vesicle from its value
of 0 mV in 0.1 M KCI (data not shown). PKC(19-36)
binds strongly to the PG and PS vesicles: 1 ,uM peptide
reduces the magnitude of the zeta potential from -70
to -30 mV (open squares). This peptide, like all the basic
peptides we have examined, binds equally well to PS and
PG vesicles.
The effect of mass action is most easily demonstrated
by comparing the concentration of peptide required to
reduce the zeta potential to the same value for PC/PS
vesicles of different composition. When the zeta poten-
tial is the same, the nonspecific electrostatic accumula-
tion of the peptide in the aqueous diffuse double layer is
also the same. Consider the concentrations of peptides
required to reduce the zeta potential to -30 mV: PS and
2:1 PC/PS vesicles require peptide concentrations of 1
and 30 ,uM, respectively (Fig. 2). Thus reducing the
negative lipid content of the membrane reduces the
binding affinity of the vesicle for the peptide by a mass
action (third set of large parentheses in Eq. 2) as well as
an electrostatic (first set of large parentheses in Eq. 2)
mechanism.
If we lower the concentration of KCl from 0.1 M (Fig.
2) to 0.01 M (Fig. 3), the zeta potential (approximately
surface potential) of a charged vesicle becomes more
negative, as predicted by the Gouy-Chapman theory.
(Compare the points at the left of the graphs in Figs. 2
and 3, which were obtained in the absence of peptide).
The effective binding constant of the peptide with the
membrane (K in Eqs. 1 and 2) increases because of the
Boltzmann term in Eq. 2, as illustrated by the results in
Fig. 1. This dependence ofKon salt concentration is also
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FIGURE 2 The effect of the PKC(19-36) peptide on the zeta potential
of PS and PG (open squares), 2:1 PC/PS (open triangles), 5:1 PC/PS
(open circles), and PC (filled circle) vesicles. The aqueous solution
contained 0.1 M KCI buffered to pH 7.0 with 1 mM MOPS. Identical
results were obtained with PG and PS vesicles and the measurements
were averaged to produce the open squares.
apparent from a comparison of Figs. 2 and 3. For
example, 10 ,uM peptide has no effect on the zeta
potential of a 5:1 PC/PS vesicle in 0.1 M KCl (open
circles in Fig. 2), whereas 1 ,uM peptide reduces the zeta
potential of a 5:1 vesicle in 0.01 M KCI from -70 to -30
mV (open circles in Fig. 3). The effects of PKC(19-36) on
the zeta potentials of PC/PS vesicles in 0.01 M KCl (Fig.
3) are very similar to those of Lys5, another pentavalent
0
-
z
< _40
z
-60
0~
-80
L-J
N
-100
0
-. 0 A -
0 Ano A A
o 1a O aA O A v
v i
o
V0
0
'/
-6 -5
log1o[PKC(19-36)] (M)
E
z
w
lLu
0
a-
Lu
N
logio[PKC(19-29)] (M)
FIGURE 4 The effect of the PKC(19-29) peptide on thet zeta poten-
tial PS (open squares), 2:1 PC/PS (open triangles), and PC (filled circles)
vesicles. The aqueous solution contained 0.1 M KCI buffered to pH 7.0
with 1 mM MOPS.
peptide (see Fig. 4 in reference 38). The results illus-
trated in Fig. 3 can be described theoretically4 by the
same combination of Gouy-Chapman, Boltzmann, and
mass action equations we used to describe the Lys5
results (see Fig. 5 of reference 38). We discuss the
limitations of our simple model in the Appendix.
We studied PKC(19-29), which lacks the Asn-Val-Glu-
Val-Lys-Asn sequence of PKC(19-36), to compare the
peptides' binding to membranes. Both peptides have a
net charge of +5, but PKC(19-29) has five basic and zero
acidic residues. A comparison of Figs. 4 and 2 illustrates
that PKC(19-29) binds with about the same affinity as
PKC(19-36) to 2:1 PC/PS membranes (but with less
affinity to PS membranes, for reasons that are not clear).
There is no specificity in the binding of the PKC(19-29)
peptide to PS vs PG; the data (not shown) we obtained
with PG vesicles are identical to the PS data illustrated
in Fig. 4. Similar data were also obtained with phospha-
tidic acid vesicles (data not shown). PKC(19-29), like
PKC(19-36) and Lys5, binds less strongly to the 2:1
PC/PS vesicles than to PS vesicles, which suggests it
binds with a stoichiometry > 1 to the negative lipids in
the vesicle. Finally, it is similar to all the other basic
peptides we have studied in that it does not bind
significantly to PC vesicles (filled circles, Fig. 4). The fit
of the theoretical curves illustrated in Fig. 3 B of refer-
ence 38 to the data for PKC(19-29) is about as good as
for Lys5.
We also measured how a known concentration of
4The data in Fig. 3 can be described qualitatively by the theoretical
curves in Fig. 5 C of reference 38. These curves were drawn with the
effective valence, zeff = z = 5, and a macroscopic intrinsic association
constant of 20 MW. We repeated the calculations using a microscopic
intrinsic constant of 20: the curves are shifted about a factor of two to
the left (stronger binding) than the curves in Fig. 5 C. We can obtain a
better fit to the data if we assume that zff = 4, and that k = 21 M'.
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FIGURE 3 The effect of the PKC(19-36) peptide on the zeta potential
of PS (open squares), 2:1 PC/PS (open triangles), 5:1 PC/PS (open
circles), 10:1 PC/PS (filled squares), and 20:1 PC/PS (open inverted
triangles), and PC (filled circle) vesicles. The aqueous solution con-
tained 0.01 M KCI buffered to pH 7.0 with 1 mM MOPS.
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FIGURE 5 Effect of PS large unilamellar vesicles (LUVs) on the free
concentration of the peptide PKC(19-29) in a 0.01 M KCI, 1 mM
MOPS, pH 7 solution. The ordinate represents the fraction of peptide
free in solution (logarithmic scale), measured relative to the total
peptide concentration of 3 F.M. The abscissa represents the concentra-
tion of PS accessible to the peptide (one-half total lipid for these
LUVs), measured relative to the total concentration of peptide. The
open circles represent the experimental measurement (n = 20). The
solid curve is the prediction of Eq. 2, using an effective valence ofzdf =
3.0 and a binding constant k = 21 M'. The dashed curve illustrates the
prediction of Eq. 2 with Ze, = z = 5 and k = 21 MW. In both curves we
assumed the binding constant of potassium ions with PS was 3 M` to
describe accurately the zeta potential data obtained in the absence of
peptide.
large unilamellar vesicles decreases the free concentra-
tion of the peptide PKC(19-29). The results we obtained
in 0.01 M KCl with PKC(19-29) and PS vesicles are
illustrated in Fig. 5: note the precipitous decrease in the
free concentration of peptide when the lipid concentra-
tion doubles.5 When the lipid concentration (measured
relative to the total peptide concentration of 3 ,uM)
increases from four to eight, the free concentration of
peptide decreases by three orders of magnitude. This
behavior contrasts markedly to the binding one observes
with neutral solutes. In that case, the free concentration
of a neutral peptide that binds to lipid is given by [P] =
[P'°']/(1 + K[L]), where [P"t] is the total concentration
of peptide, K is an association constant, and [LI is the
concentration of lipid. Doubling the lipid concentration
reduces the free concentration of the neutral peptide
twofold at most. We observe the large effects seen in Fig.
5 because the magnitude of the electrostatic potential
adjacent to the lipid vesicles increases as less peptide is
available to bind to the membranes. This markedly
increases the effective binding constant (K in Eqs. 1 and
5We obtained similar results to those illustrated in Fig. 5-precipitous
reduction in free peptide concentration as predicted by theory-for
Lys, as well as PKC(19-29). We made measurements in 0.1 M KCI with
PS vesicles and in 0.01 M KCI with PS and 2:1 PC/PS vesicles (data not
shown).
2), which is proportional to the Boltzmann term. The
two theoretical curves in Fig. 5 illustrate the importance
of using an effective rather than the actual valence in the
Boltzmann expression. The dashed curve is drawn from
Eq. 2 with Zeff = z = 5, whereas the solid curve is drawn
with Zeff = 3.0, the value that gave a best fit to the zeta
potential versus PKC(19-29) measurements (see Appen-
dix). The solid curve provides a much better fit to the
experimental data.
DISCUSSION
Our main objective was to measure how strongly pep-
tides that mimic the pseudosubstrate region of PKC bind
to membranes under physiological conditions. Fig. 1
illustrates how the binding of PKC(19-36) depends on
the mol % negative lipid in the membrane. The cytoplas-
mic surface of a plasma membrane typically contains
between 20 and 30% negative phospholipids, usually PS
for a mammalian cell (11, 49, 57, 66, 69). Fig. 6 illus-
trates how the effective binding constant depends on the
mol % of negative lipid in the membrane, as deduced
from the data in Fig. 1 using Eq. 1. The effective binding
constant is of order 1 ,im for a membrane with 25 mol %
negative lipid. In other words, one must go a distance
x = 1 ,im away from a planar membrane of areaA to find
the same number of peptides bound to the membrane
and in the volume Ax. By making certain assumptions,6
we can express this effective binding constant in more
conventional units, such as 104 M', which corresponds
to a net free energy change of 6 kcal/mol.
We now consider the implications of our study to the
activation of PKC. As we illustrate in Fig. 7, PKC
consists of a regulatory domain with a pseudosubstrate
region (foot) and a kinase domain with a substrate-
binding site (mouth). The work of House and Kemp (30)
and of Makowske and Rosen (44) suggests that in the
cytoplasm of a quiescent cell, this extremely flexible (25)
enzyme resembles the title of a Bellow (6) story: "Him
With His Foot in His Mouth". House and Kemp (30)
showed that a peptide corresponding to amino acids
6We can express the effective binding constant K in more conventional
units, such as Molar-', by following other investigators (17, 18, 61, 63)
and assuming that the binding of a peptide, P, to n acidic lipids, L, can
be described by the equation: K' = n[PLJ/[L][P]. To convert our
effective binding constant K into the association constant K' we divide
both sides of Eq. 1 by the free surface concentration of PG and
multiply them by the assumed number of lipid molecules that bind to
the peptide, i.e., four. Each lipid occupies - 0.7 nm2, so the effective
binding constant of K = 1 ,um for the binding of PKC(19-36) to a
membrane with 25 mol% negative lipid corresponds to an association
constant K' = 6.7 103 M-' 104 M-', which is equivalent to a net free
energy change on binding ofRT ln (K'), or - 6 kcal/mol.
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FIGURE 6 The effective binding constant, K, for the peptide PKC(19-
36), plotted as a function of the mol percent negatively charged lipid in
the membrane. The value of K was deduced from the data in Fig. 1
using Eq. 1 (Open circles) 0.1 M KCI. (Filled circles) 0.01 M KCI.
19-31 of PKC is as effective as peptide 19-36 in
inhibiting substrate phosphorylation; this 19-31 region
contains 5 basic (and no acidic) amino acids. These five
basic amino acids are represented in the cartoon (Fig. 7)
as the five positively charged toes of the pseudosubstrate
foot. The positive charges are important for function
(30,31,45). These five basic residues possibly interact with
acidic residues in the putative substrate binding site (32).
Our working hypothesis is that the interaction of the
pseudosubstrate region with acidic lipids facilitates the
activation of PKC. Our measurements allow us to rule
out the simple possibility that in the presence of calcium
the enzyme removes its foot from its mouth, and the
binding of the positively charged toes to the negatively
charged lipids causes concomitant translocation and
activation of the enzyme. The effective binding constant
of the PKC peptides we measured6 to membranes with
25% negative lipid (K = 1 ,um, or K' = 104 M-1, or net
free energy change = 6 kcal/mol) is too weak to account
for the observed binding of PKC to vesicles upon
exposure to calcium. According to Bazzi and Nelsesteun
(4), the effective binding constant of the protein is > 108
M` (or the net free energy change is > 12 kcal/mol) for
vesicles containing 30% PS. Thus the protein binds with
at least 6 kcal/mol more free energy to the membranes
even though the protein loses more translational and
rotational free energy than the peptide when it binds
(10, 19, 35).
Evidence from several laboratories suggests that cal-
cium ions can cause PKC to bind to the membrane
without removing the foot from the mouth: in the
absence of DAG binding to PC/PS vesicles can occur
without activation (4, 22, 59). Once the enzyme has
bound to the membrane, DAG and PS might act
together to help pull the foot out from the mouth and
thus activate PKC. Our measurements with PKC(19-29)
and PKC(19-36) peptides demonstrate that - 6 kcal/mol
free energy will be gained if the basic toes bind to acidic
lipids when the pseudosubstrate region is removed from
the substrate binding site. How much free energy is
required to remove the foot from the mouth? We can
crudely estimate it is 10 kcal/mol from the observation
that about 100 nM pseudosubstrate peptide is required
to inhibit PKC (30). Thus the free energy recovered by
interaction with negative phospholipids (6 kcal/mol for a
25 mol% PS membrane) can stabilize the active state of
the enzyme but is not sufficient to fully activate the
enzyme in the absence of DAG. Our hypothesis is
consistent with the observation that less DAG is re-
quired as the mol % PS in the membrane increases (27).
In summary, acidic lipids may be involved in both the
calcium-induced binding of PKC to the membrane, a
process that is not understood (5, 43), and the activation
of the enzyme. Observations in the literature provide
three lines of support for the hypothesis that acidic lipids
stabilize the active form of PKC by binding to basic
residues in the pseudosubstrate region, as illustrated in
Fig. 7. First, the activation of PKC and the binding of
pseudosubstrate peptides to a membrane both depend
on the mol fraction of negative lipid in the membrane in
a sigmoidal manner.7 Several groups have demonstrated
that the rate at which PKC phosphorylates either sub-
strates or itself is a sigmoidal function of the mol% PS in
a micelle (12, 26, 28, 29, 34, 52, 58) or membrane (53).
The steepness of the sigmoidal curve (Hill coefficient)
depends on the nature of the surface, the substrate, and
the PKC isotype. Hannun and Bell (26) showed their
sigmoidal dependence of PKC activity on mol% PS was
consistent with a Hill coefficient =5, as was the binding
of the PKC(19-36) peptide in Fig. 1; the dashed line in
Fig. 1 is drawn with a Hill coefficient of 5. Larger Hill
coefficients are obtained with the purified a and m
isotypes of PKC (12, 52). Second, the observation that
PKC activation occurs with 100% PS vesicles in the
absence of DAG (62) is consistent with our simple
hypothesis. Fig. 6 (see also Figs. 1 and 2) illustrates that
the effective binding constant of the pseudosubstrate
peptide to membranes is a steep function of the mol%
acidic lipid-the net free energy change upon binding
increases from -6 to > 10 kcal/mol when the mol%
negative lipid increases from 25 to 100%. Thus the free
energy change on binding to a 100% PS membrane is
'The binding of the pseudosubstrate region of PKC to anionic lipids
may differ from that of the PKC(19-36) peptide because their
structures may be different. Even if their structures are similar, the
degree of apparent cooperativity or Hill coefficients for the two
processes may be different because the interaction of the pseudosub-
strate region of PKC with acidic lipids may involve several binding
steps, as illustrated in Fig. 7.
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sufficient to compensate for the energy required to
remove the pseudosubstrate region from the substrate
binding site. Third, Eq. 2 demonstrates that adsorption
of basic amphiphiles to membranes should reduce bind-
ing of basic peptides to membranes by reducing the
magnitude of the surface potential. Many observations
(21) suggest that chemically diverse basic amphiphiles
such as tetracaine (50) and trifluoperazine (39, 67)
inhibit PKC. Tetracaine and trifluoperazine adsorb
strongly to bilayer membranes at the concentrations
used in these experiments ( - 1 and 0.1 mM) and do
change the surface potential (48).
The observation that PS activates PKC more effec-
tively than other anionic lipids such as PG and PA
(12, 26, 34, 42,52) would appear to argue against the
hypothesis illustrated in Fig. 7 because we observe little
selectivity in the binding of the PKC peptides to the
acidic lipids PS, PG, and PA. Complete activation of
PKC, however, requires phorbol esters or DAG as well
as calcium and acidic phospholipids. Phorbol esters bind
more effectively to enzyme-phospholipid complexes con-
taining PS than to complexes containing either PA or
PG and this could account for the selectivity observed
(26, 34).
Cai++
FIGURE 7 Cartoon illustrating our working hypothesis about the
activation of PKC. The filled circles represent the polar head groups of
negatively charged phospholipids, such as PS, which are located
preferentially on the cytoplasmic monolayer of the plasma membrane.
The open circles represent the head groups of zwitterionic lipids, such
as PC, to which positively charged amino acids do not bind. Protein
kinase C, PKC, has a kinase domain with a substrate binding site
(mouth) and a regulatory domain with a pseudosubstrate region (foot)
that contains five positively charged amino acids (toes). The experi-
ments of House and Kemp (30) and Makowske and Rosen (44) suggest
that PKC has its foot in its mouth when it is in the cytoplasm.
Experiments from several different laboratories suggest calcium ions
can cause PKC to bind to the membrane but do not cause activation;
this translocation requires acidic lipids and the mechanism is not
understood. We hypothesize that binding of basic residues in the foot
region to acidic lipids in the membrane (and concomitant binding of
the adjacent DAG binding site on PKC to DAG in the membrane)
then activates the enzyme by compensating for the free energy
required to remove the foot from the mouth. Our measurements with
peptides indicate the binding of the pseudosubstrate region to nega-
tive lipids should decrease the free energy of the activated form of the
enzyme by - 6 kcal/mol.
APPENDIX
There are three major limitations to our simple model. First, we must
assume the effective valence of the peptides that appears in the
Boltzmann relation, Zeff in Eq. 2, is about half the actual valence.
Second, the intrinsic microscopic association constant appears to
decrease when the mole fraction of anionic lipid in the membrane
decreases. Third, we have no direct information about the number of
binding sites for anionic lipids on the peptides.
We initially assumed that Zeff = z = 5 and attempted to fit the
experimental data presented in Figs. 1-5 with our model (Eqs.
4, 6-13, 8a-1la in reference 38), which has only one free parameter,
the intrinsic microscopic association constant of a basic residue with an
acidic lipid, k. The slopes of the curves illustrated in Figs. 2-4,
however, were larger than the theoretically predicted values. The
limiting theoretical slope is 58 mV/zeff = 11 mV/decade peptide
concentration if Zeff = 5. To account for the slopes of the experimental
data we allowed z,ff to be a free parameter and obtained the following
values of zff: 4 (Fig. 2, PS membrane), 2.5 (Fig. 2,2:1 PC/PS), 4 (Fig. 3,
all membranes), and 2 (Fig. 4, PS). The necessity of choosing Zeff < Z
was also apparent from the experimental results illustrated in Fig. 5:
the dashed curve represents predictions of the model with Zeff = Z = 5
and k = 21 M'. We obtained better agreement between theory and
experiment by assumingZeff = 3 (solid curve), a value that also yields the
best fit for the effect of PKC(19-29) on the zeta potential of a PS
membrane in 10 mM KCl (not shown). The filtration binding data
illustrated in Fig. 1 also indicate that Z,ff < 5. The data can be
described ifz = Z,ff = 5 and k = 0.3 MW. This value of k, however, is <
the value deduced from other measurements on vesicles that had more
bound peptide and a less negative surface potential. To reconcile the
two sets of measurements, we assumed Zef = 2.5, which gave the best fit
to the slope of the zeta potential curve for PKC(19-36) and 2:1
PC/PS(PG) membranes in 100mM KCI (Fig. 2). Avalue ofk = 3.5 M-'
then provided an adequate fit to the data in Fig. 1 (see solid curve) as
well as agreeing better with values for k obtained from other
measurements made under different conditions. Other large basic
peptides, such as melittin (10, 40, 64) and pentalysine (38), also appear
to have lower effective valences. We list some reasons that Zcff is about
half the value ofz for these large peptides in footnote 1.
The value ofk obtained from a least squares fit to the zeta potential
data obtained with different PC/PS membranes is not a constant, but
decreases as the mole fraction of acidic lipid decreases. For PKC(19-
36) in 100mM KCl, k = 10, 6, and 3 M' for 0:1, 2:1, and 5:1 PC/PS or
PC/PG membranes, respectively. The direct binding measurements in
Fig. 1 also illustrate the dependence of the microscopic association
constant on the mol fraction of acidic lipid: the theoretical binding
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curve calculated for k = 3.5 M` (solid line) overestimates the fraction
of bound peptide to the membranes with a low mol% PG and
underestimates the fraction bound to membrane with a high mol%
PG. We do not understand the reasons for this deviation from the
simple mass action formulation.
The peptides PKC(19-29) and PKC (19-36) have five and six basic
residues, respectively, and each basic residue is a potential binding site
for acidic lipids. More extensive studies on another pentavalent
peptide, Lys5, suggest it has four binding sites for acidic lipids (38), and
in the absence of direct information we assume the PKC(19-29) and
PKC(19-36) also have four binding sites.
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